Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It
Posted in

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It

“Giant cell arteritis requires ongoing management, but it does not necessarily require continuous treatment.” In 2017, tocilizumab (Actemra), a biologic drug that inhibits interleukin-6 (IL-6), was FDA-approved for giant cell arteritis — an inflammation of…

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It Read More
Good News for Pregnant Women with Arthritis: Most Babies Exposed to Biologics in Utero Don’t Get Serious Infections
Posted in

Good News for Pregnant Women with Arthritis: Most Babies Exposed to Biologics in Utero Don’t Get Serious Infections

Although biologics cross the placenta, research shows they lead to few infections in babies after they’re born. The prospect of pregnancy can be daunting for women with inflammatory arthritis. Not only can disease flares occur,…

Good News for Pregnant Women with Arthritis: Most Babies Exposed to Biologics in Utero Don’t Get Serious Infections Read More